Claire C. Davies

Claire C. Davies

Auto-generated profile, based on publicly available information

Claire C. Davies

Baptist Health Lexington

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2024 in Medical Oncology
Verified
Journal Article
Open access
PDF file
LGLaura Gilchrist
Laura Gilchrist
KLKim Levenhagen
Kim Levenhagen
CDClaire C. Davies
Claire C. Davies
LKLinda Koehler
Linda Koehler
Breast cancer-related lymphedema (BCRL) remains a challenging condition impacting function and quality of life. Complete decongestive therapy (CDT) is the current standard of care, necessitating a comprehensive review of its impact. This paper presents a systematic review (SR) of SRs on CDT’s efficacy in BCRL, and the components of manual lymph drainage (MLD) and exercise. A literature search yielded 13 SRs published between January 2018 and March 2023 meeting inclusion criteria, with varied quality ratings based on the AMSTAR II. A sub-analysis of CDT investigated the within group effect size estimations on volume in different stages of lymphedema. While a moderate quality SR indicated support for CDT in volume reduction, other SRs on the topic were of critically low quality. Larger effect sizes for CDT were found for later stage BCRL. The impact of MLD as a component of CDT demonstrated no additional volume benefit in a mix of moderate to low quality SRs. Similarly, exercise’s role in volume reduction in CDT was limited, although it demonstrated some benefit in pain and quality of life. A rapid review of trials published January 2021–March 2023 reinforced these findings. Variability in CDT delivery and outcomes remained. These findings underscore the need to standardize staging criteria and outcome measures in research and practice. Future research should focus on refining interventions, determining clinically important differences in outcomes, and standardizing measures to improve evidence-based BCRL management. Current evidence supports CDT’s efficacy in BCRL. MLD and exercise as components of CDT have limited support for volume reduction.

1 January 2014 in Rehabilitation Oncology
Verified
Journal Article
Open access
CDClaire PT Davies
Claire PT Davies
KRKathryn Pt Ryans
Kathryn Pt Ryans
KLKim Pt Levenhagen
Kim Pt Levenhagen
MPMarisa Pt Perdomo
Marisa Pt Perdomo
Background: Breast cancer survivors who develop lymphedema report a wide range of upper extremity impairments and functional limitations. The reported impairments can lead to difficulty with activities of daily living and a reduction in quality of life. It is important for physical therapists to assess and measure these functional deficits and their effect on quality of life using a reliable outcome measure. Purpose: The purpose of the Breast Cancer EDGE Task Force subgroup review was to identify specific outcome measurement tools that could be recommended to measure quality of life and functional deficits in patients with breast cancer related lymphedema (BCRL). Methods: A systematic literature review was used to appraise the evidence supporting the psychometric properties and clinical utility of outcome measures assessing quality of life and function in patients with BCRL. Results: The Functional Assessment of Cancer Therapy - Breast (FACT-B+4) and Disability of Arm, Shoulder and Hand (DASH) questionnaires received a recommendation of 4, highly recommended for use in patients with BCRL due to their psychometric properties and clinical utility. Three other outcome measures were reviewed. The Lymphoedema Functioning, Disability and Health Questionnaire (Lymph -ICF) and the Upper Limb Lymphedema Measure (ULL-27) received a recommendation of 2A, unable to recommend at this time. The Lymphedema Quality of Life Measure for Limb (LYMQOL) received a 1, not recommended. Conclusion: The Breast Cancer EDGE Task Force recommends the FACT-B+4 and DASH questionnaires to assess the quality of life and function in patients with BCRL. The Lymph-ICF and ULL-27 and LYMQOL tools cannot be recommended at this time. Further research is recommended to determine reliability, validity, and clinical utility of these outcome measures. Other shoulder functional outcome measures that are validated in other patient populations needs to be investigated to determine if application to the BCRL population is appropriate.

1 January 2010 in Rehabilitation Oncology
Verified
Journal Article
Closed access
CDClaire C. Davies
Claire C. Davies
DBDorothy Y. Brockopp
Dorothy Y. Brockopp
Hypersensitive adhesions that lead to decreased flexibility and function in the involved upper quadrant can develop following mastectomy for breast cancer. ASTYM® treatment has been used to desensitize and remodel scar tissue thereby improving function. This pilot study was designed to evaluate the effectiveness of ASTYM on range of motion and perception of functional ability in this population. A retrospective, descriptive design was used to evaluate functioning before and after ASTYM. Data retrieved from patients' charts included: demographics, ASTYM treatment use, range of motion, and perceived disability. Data analysis revealed significant (p < .000) and clinically meaningful findings related to increased range of flexion and abduction motion and perception of physical disability in breast cancer patients following ASTYM treatment. Problems with upper extremity motion, disability, and self perception are common in this population. ASTYM is effective in returning women to their prior physical status following surgery.

1 September 2017 in Cancer Nursing
Verified
Journal Article
Closed access
PDF file
CDClaire C. Davies
Claire C. Davies
DBDorothy Brockopp
Dorothy Brockopp
KMKrista Moe
Krista Moe
PWPeggy Wheeler
Peggy Wheeler
JAJean Abner
Jean Abner
ALAlexander Lengerich
Alexander Lengerich
Background: In 2014, it is estimated that 232,670 new cases of breast cancer occurred in the United States. Unilateral or bilateral mastectomy is a frequently chosen option for treating this disease. Objective: The purpose of this study was to explore, through an in-depth interview process, the lived experience of women immediately following mastectomy when they see their scars for the first time. Methods: Purposeful sampling was used until saturation was reached. In-depth interviews were conducted with 10 women related to their mastectomy experience. The data were analyzed using a phenomenological approach. Results: The following 8 themes emerged from the data; lasting impact, personal impact, relational impact, gratitude, support system, coping strategies, timing, and discomfort. Conclusions: The results of the study provide evidence that women face ongoing challenges following seeing their mastectomy scars for the first time that is not adequately addressed by healthcare professionals. Implications for Practice: Nurses and other healthcare professionals need to gain a better understanding of the difficulties perceived by women following seeing the scars from mastectomy and implement strategies to assist in successful adaptation to the experience.

2 November 2024 in Medical Oncology
Verified
Journal Article
Open access
PDF file
SDShelley DiCecco
Shelley DiCecco
CDClaire C. Davies
Claire C. Davies
LGLaura Gilchrist
Laura Gilchrist
KLKim Levenhagen
Kim Levenhagen
MLMarie-Eve Letellier
Marie-Eve Letellier
LKLinda Koehler
Linda Koehler
This document was drafted by interdisciplinary experts informed by the evidence and guided by their extensive lymphedema clinical experience at the 2023 American Cancer Society (ACS) Lymphedema Summit: Forward Momentum: Future Steps in Lymphedema Management hosted by the ACS, Lymphology Association of North America, and the Washington School of Medicine in St. Louis, Missouri. Consensus statements were derived from a facilitated workshop and multiple follow-up discussions and meetings combining available evidence and clinical expertise. The consensus statements find that the essential components of complete decongestive therapy (CDT) are examination, compression, manual techniques (this may include but is not limited to manual lymph drainage), exercise, skin care, education, and self-management. Adjunctive interventions and alternatives may complement CDT. CDT should be provided by specifically trained healthcare practitioners in lymphedema management, preferably a certified lymphedema therapist. The individual’s lymphedema etiology and presentation, comorbidities, and other pertinent clinical information will determine the components of CDT applied and the frequency and duration of care.

1 January 2014 in Rehabilitation Oncology
Verified
Journal Article
Open access
MFMary Insana Fisher
Mary Insana Fisher
CDClaire Davies
Claire Davies
CBChristine Beuthin
Christine Beuthin
GCGenevieve Colon
Genevieve Colon
BZBrittany Zoll
Brittany Zoll
LPLucinda Pfalzer
Lucinda Pfalzer
Muscular strength deficits are a common morbidity following treatment for breast cancer. Accurate assessment of strength and muscular endurance following breast cancer treatments is essential in identifying deficits and planning rehabilitation strategies. The purpose of this systematic review was to identify strength and muscular endurance outcome measures for use with women treated for breast cancer that possess strong psychometric properties and are clinically useful. Multiple electronic databases were searched between February and June 2013. Included studies of tools used to assess strength and muscular endurance met the following criteria: reported psychometric properties, clinically feasible methods, adults (preferably female), and published in the English language. Each outcome measure was reviewed independently and rated by two reviewers separately. A single Cancer EDGE Task Force Outcome Measure Rating Form was completed for each category of strength or endurance assessment, and a recommendation was made using the 4-point Breast Cancer EDGE Task Force Rating Scale. Of the original 874 articles found, 22 were included in this review. Hand Grip Strength and Hand Held Dynamometry were rated 3, recommended for clinical use. Manual muscle test and one repetition maximum were rated 2B, unable to recommend at this time. Muscular endurance testing was rated 2A, unable to recommend at this time. Utilizing objective dynamometry for hand grip and muscle strength testing provides precise measurement to assess baseline status and monitor change among women treated for breast cancer.